Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ACAD acadia.com
Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for neurological and rare diseases. The company's commercial portfolio includes NUPLAZID (pimavanserin), a selective serotonin inverse agonist approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), approved for the treatment of Rett syndrome in adults and pediatric patients. DAYBUE is also available in a STIX formulation. Acadia's pipeline includes remlifanserin, currently in a Phase 2/3 RADIANT program for Alzheimer's disease psychosis, for which the FDA has granted Fast Track designation. The company is also pursuing opportunities in Lewy body dementia psychosis and other neurological indications. Acadia is pursuing European regulatory approval for trofinetide (branded as DAYBU in Europe) for Rett syndrome following a positive CHMP opinion from the EMA. Updated
Wednesday's top analyst upgrades and downgrades included Amazon.com, Arm, Corning, Dollar General, Electronic Arts, Estee Lauder, Juniper Networks, Next Era Energy Partners, Realty Income, Rivian Automotive, Sabra Healthcare REIT and Starwood Property…
Friday's additional top analyst upgrades and downgrades included Acadia Pharmaceuticals, BioCryst Pharmaceuticals, Duke Energy, Kellogg, Paramount Global, Rhythm Pharmaceuticals and Teva Pharmaceutical Industries.
Citigroup takes a look at a couple stocks with potentially huge upside and where they could go in light of a possible recession.
Wednesday's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Chevron, Compass, ConocoPhillips, Kraft Heinz, Micron Technology, Netflix, Nike, Seagate Technology, Shoals Technologies and WestRock.
Tuesday's additional top analyst upgrades and downgrades included Acadia Pharmaceuticals, CarGurus, CubeSmart, Etsy, Keurig Dr Pepper and Molson Coors Beverage.
Friday's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Accenture, Amgen, AutoZone, Azek, Boeing, Dollar General, Etsy, Fidelity National Information Services, FedEx, NexTier Oilfield Solutions, S&P Global, Unity Software and Warner Bros.…
Wednesday afternoon's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.
Wednesday afternoon's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Enphase Energy, General Motors, Incyte, Lyft, MP Materials, Newmont, Tenet Healthcare and Vale.
Wednesday afternoon's top analyst upgrades and downgrades included Adobe, Altria, Amgen, Beyond Meat, BP, Murphy Oil, Northrop Grumman, Occidental Petroleum, Peloton Interactive, Pfizer, Salesforce.com and 3M.
Wednesday's early top analyst upgrades and downgrades included Biogen, Goodyear Tire, Hippo, Krispy Kreme, Lockheed Martin, Micron Technology, Microsoft, Nike and Patterson-UTI Energy.
Tuesday afternoon's top analyst upgrades and downgrades included Boot Barn, Cigna, Comerica, GoodRx, Oracle and United Rentals.
Monday afternoon's analyst upgrades and downgrades included Bristol-Myers Squibb, Intel, Merck, Newell Brands, Snap, Spotify Technology and Tilray.
Thursday afternoon's analyst upgrades and downgrades included Deere, NetApp, Petrobras and TJX Companies.
JMP Securities has come out with a few stock picks that it thinks will outperform in the coming months.
Tuesday's top analyst upgrades and downgrades included Airbnb, Chevron, Coupang, Freeport-McMoRan, Peloton Interactive, Snap, Wynn Resorts and Zillow.
Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for neurological and rare diseases.
24/7 Wall St.'s 12-month price target for ACAD is $33.12, rated Buy. The Wall Street consensus target is $31.95. ACAD price prediction →
